Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
暂无分享，去创建一个
E. Winer | J. Mejia | V. Karantza | F. André | N. Harbeck | K. Tamura | S. Im | N. Turner | P. Schmid | S. Ohtani | R. Dent | J. Cortés | A. Gonçalves | E. Muñoz-Couselo | O. Lipatov | I. Witzel | K. Lee | S. Zambelli | L. Testa | Xuan Zhou